Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia

Exclusion Criteria

• •1. Subject deprived from liberty by a judiciary or administrative decision, sick subject in situation of emergency.
• •2. Under age or off age subject protected by law, as well as those admitted to sanitary or social facilities, ever since the research can be performed in another manner.
• •3. Subject who cannot be contacted in case of emergency.
• •4. Females in pregnancy (positive urine pregnancy-tests performed at screening(visit 1 and visit 9)or nursing or without effective contraception method.
• •5. Subject with any systemic disorder or skin disease (e.g. scalp disorders such as seborrheic dermatitis or scalp psoriasis) or presenting genetic or hormonal alopecia.
• •6. Subject with a condition or receiving a medication which, in the opinion of the investigator, could compromise the safety of the subject or affect the outcome of the study.
• •7. Subject using topic cosmetic treatment or oral nutritional supplement likely to interfere on hair loss parameters during the last 3 months prior to the start of the study (screening)
• •8. Subject having a medical treatment likely to induce an alopecia or hypertrichosia, or having stopped it from than 3 months (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, etc...)
• •9. Subject following a long period (\>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening)
• •10. Subject following a short period (\<30 days) treatment of anti-inflammatory stopped or ongoing preceding the screening period.
• •11. Subject having a immunosuppressive and/or corticoids treatment during the 4 weeks preceding the screening period
• •12. Subject having dyed, bleached hair or with a permanent wave prior to study start.
• •13. Subject who have been exposed to excessive or intensive UV light (natural or artificial) prior to the study.